BetterLife Pharma (OTCMKTS:BETRF – Get Free Report) released its earnings results on Tuesday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
BetterLife Pharma Stock Down 6.5%
OTCMKTS:BETRF traded down $0.01 on Tuesday, reaching $0.21. 104,635 shares of the stock traded hands, compared to its average volume of 90,412. BetterLife Pharma has a 12 month low of $0.03 and a 12 month high of $0.33. The company’s fifty day simple moving average is $0.22 and its 200 day simple moving average is $0.12.
BetterLife Pharma Company Profile
BetterLife Pharma Inc is a Canadian biotechnology company focused on developing novel treatments for mental health and neurological conditions. Its research programs are centered on pharmaceutical compounds derived from or inspired by psychedelic substances, with the goal of creating therapies that may offer therapeutic benefits without the hallucinogenic effects associated with some traditional psychedelics.
The company’s development programs have included BETR-001, a synthetic derivative of lysergic acid diethylamide (LSD) being studied for potential applications in depression and other neuropsychiatric disorders, and BETR-002, an ibogaine-derived compound being investigated for substance-use disorders and related conditions.
Featured Articles
- Five stocks we like better than BetterLife Pharma
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
